Krystal Biotech, Inc. (KRYS)

Market Cap	5.41B
Revenue (ttm)	290.52M
Net Income (ttm)	89.16M
Shares Out	28.81M
EPS (ttm)	3.00
PE Ratio	62.62
Forward PE	26.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	288,471
Open	184.99
Previous Close	182.62
Day's Range	184.12 - 189.19
52-Week Range	109.57 - 219.34
Beta	0.84
Analysts	Strong Buy
Price Target	210.00 (+11.79%)
Earnings Date	Feb 19, 2025

About KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cys...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Sep 20, 2017
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: KRYS
• Website: https://www.krystalbio.com

Financial Performance

In 2024, Krystal Biotech's revenue was $290.52 million, an increase of 473.02% compared to the previous year's $50.70 million. Earnings were $89.16 million, an increase of 715.58%.

Analyst Forecast

According to 7 analysts, the average rating for KRYS stock is "Strong Buy." The 12-month stock price forecast is $210.0, which is an increase of 11.79% from the latest price.

Price Target

$210.0

(11.79% upside)

Analyst Consensus: Strong Buy